CAR-T Therapy in Leukemia: Limitations and Prospects

In the broad field of cancer management via immunotherapy, chimeric antigen receptor T-cell therapy (CAR-T therapy), commonly known as CAR-T therapy, has become a game-changing approach, particularly for patients with relapsed or refractory lymphoma. Using genetic engineering, a patient's T cells can be genetically modified to target specific tumor antigens allowing CAR-T cells to identify and destroy abnormal cells, which can provide long-term anti-tumor responses. The mechanisms and clinical applications of CAR-T therapy in leukemia, particularly in B-cell ALL and CD19-targeted CAR-T therapy will be discussed in this thesis. While CAR-T therapy shows great promise in its therapeutic ability, it faces a number of critical challenges, including insufficient efficacy against solid malignancies, on-target off-tumor effects, cytokine release syndrome (CRS), and the cost and complexity of individualized production. To overcome these issues, investigators have investigated innovations aimed at enhancing CAR-T cell stability, infiltration into tumors, and anti-tumor efficacy, such as the creation of IL-7/XCL1-armed CAR-T cells. Additionally, outcome-based reimbursement programs could help to reduce some of the financial barriers associated with CAR-T treatment. To conclude, CAR-T therapy represents a potential breakthrough in lymphoma treatment, while continued research into safety, persistence, accessibility, and cost-effectiveness is crucial to further improve the medical benefits.